Increased activation of p52 has been observed in lung6, breast15, prostate16,17, and pancreatic cancers18; however, studies on the effects of p52 activation in cancers of epithelial origin have been limited due to lack of appropriate in vivo models. Here, NFKB2 is linked to cancer.